newsfilter
← Latest News
Business Wire·

Cyteir Therapeutics Reports Third Quarter 2022 Financial Results and Operational Highlights

- Initial data from CYT-0851 monotherapy solid tumor Phase 2 cohorts are now expected in first quarter of 2023 - Initial data from Phase 1 combination solid tumor cohorts are expected in first half of 2023 - Ended